CRDL vs. RGNX, CRGX, ITOS, VALN, HLVX, EXAI, TSHA, KYTX, ADPT, and LXEO
Should you be buying Cardiol Therapeutics stock or one of its competitors? The main competitors of Cardiol Therapeutics include REGENXBIO (RGNX), CARGO Therapeutics (CRGX), iTeos Therapeutics (ITOS), Valneva (VALN), HilleVax (HLVX), Exscientia (EXAI), Taysha Gene Therapies (TSHA), Kyverna Therapeutics (KYTX), Adaptive Biotechnologies (ADPT), and Lexeo Therapeutics (LXEO). These companies are all part of the "biological products, except diagnostic" industry.
REGENXBIO (NASDAQ:RGNX) and Cardiol Therapeutics (NASDAQ:CRDL) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, profitability, earnings, community ranking, media sentiment, risk, analyst recommendations, institutional ownership and dividends.
REGENXBIO received 407 more outperform votes than Cardiol Therapeutics when rated by MarketBeat users. Likewise, 65.74% of users gave REGENXBIO an outperform vote while only 54.84% of users gave Cardiol Therapeutics an outperform vote.
REGENXBIO currently has a consensus target price of $38.64, indicating a potential upside of 169.24%. Cardiol Therapeutics has a consensus target price of $7.00, indicating a potential upside of 167.18%. Given Cardiol Therapeutics' higher possible upside, equities research analysts clearly believe REGENXBIO is more favorable than Cardiol Therapeutics.
Cardiol Therapeutics has lower revenue, but higher earnings than REGENXBIO. Cardiol Therapeutics is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks.
88.1% of REGENXBIO shares are owned by institutional investors. Comparatively, 12.5% of Cardiol Therapeutics shares are owned by institutional investors. 13.1% of REGENXBIO shares are owned by insiders. Comparatively, 5.3% of Cardiol Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
REGENXBIO has a beta of 1.38, indicating that its stock price is 38% more volatile than the S&P 500. Comparatively, Cardiol Therapeutics has a beta of 0.87, indicating that its stock price is 13% less volatile than the S&P 500.
Cardiol Therapeutics has a net margin of 0.00% compared to Cardiol Therapeutics' net margin of -299.96%. Cardiol Therapeutics' return on equity of -70.72% beat REGENXBIO's return on equity.
In the previous week, REGENXBIO had 3 more articles in the media than Cardiol Therapeutics. MarketBeat recorded 5 mentions for REGENXBIO and 2 mentions for Cardiol Therapeutics. REGENXBIO's average media sentiment score of 1.44 beat Cardiol Therapeutics' score of 0.69 indicating that Cardiol Therapeutics is being referred to more favorably in the news media.
Summary
REGENXBIO beats Cardiol Therapeutics on 12 of the 18 factors compared between the two stocks.
Get Cardiol Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRDL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CRDL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cardiol Therapeutics Competitors List
Related Companies and Tools
